Astria Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ATXS Nasdaq 2836 www.astriatx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Astria Therapeutics, Inc.

Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE - Jan 13th, 2025 1:00 pm
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 3rd, 2025 9:10 pm
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE - Dec 11th, 2024 1:00 pm
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis - Dec 10th, 2024 1:00 pm
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - Nov 13th, 2024 9:10 pm
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference - Nov 13th, 2024 1:00 pm
Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting - Oct 30th, 2024 12:00 pm
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting - Oct 21st, 2024 12:00 pm
Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth - Oct 18th, 2024 12:50 pm
European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema - Oct 16th, 2024 12:00 pm
Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema - Sep 30th, 2024 12:00 pm
Astria Therapeutics to Present at Upcoming Global Angioedema Forum - Sep 27th, 2024 12:00 pm
Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress - Sep 19th, 2024 12:00 pm
Astria Therapeutics to Present at Upcoming Bradykinin Symposium - Aug 30th, 2024 12:00 pm
Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference - Aug 29th, 2024 12:00 pm
Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update - Aug 12th, 2024 8:10 pm
Astria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema - Aug 12th, 2024 8:00 pm
Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference - Aug 7th, 2024 12:00 pm
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference - May 30th, 2024 12:00 pm
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference - May 24th, 2024 12:00 pm